8-K: Fractyl Health Reports Positive Clinical Data for Obesity and Diabetes Treatments, Highlighting Revita's Weight Maintenance and Rejuva's Preclinical Success

Fractyl Health, Inc. announced positive 3-month data from its Revita REMAIN-1 pivotal study, showing sustained weight loss after GLP-1 discontinuation, alongside promising preclinical data for its Rejuva gene therapy platform for obesity and type 2 diabetes.

Summary

• Fractyl Health reported positive 3-month data from the REVEAL-1 cohort of its REMAIN-1 pivotal study for Revita, a procedure aimed at weight maintenance after GLP-1 discontinuation.
• 12 of 13 participants (over 90%) either lost or maintained their weight at 3 months post-GLP-1 discontinuation and a single Revita procedure, with 6 of 13 experiencing further weight loss.
• Median weight remained stable through 3 months (0.46% / ~1 pound weight change), significantly contrasting with the typical 5-6% (10-15 pounds) weight regain observed in studies like SURMOUNT-4 after GLP-1 therapy cessation.
• Revita demonstrated excellent tolerability with no unanticipated or serious adverse effects, and only 3 of 13 participants experienced mild, transient Grade I treatment-emergent adverse effects.
• The company also announced new preclinical data for its Rejuva Smart GLP-1 pancreatic gene therapy platform, presented at the American Diabetes Association's 85th Scientific Sessions.
• Preclinical data showed that a single dose of Rejuva was well-tolerated in healthy animals and prevented obesity and hyperglycemia in animals exposed to a high-fat diet, resulting in a 20% reduction in body weight and a 38% decrease in blood glucose by day 21 in a diet-induced obesity model.
• These findings support the advancement of RJVA-001, Rejuva's first clinical candidate, toward first-in-human studies, with preliminary clinical data anticipated in 2026.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical and preclinical data for both of the company's lead programs, Revita and Rejuva. The Revita data significantly outperforms typical outcomes for weight maintenance post-GLP-1 discontinuation, and the Rejuva preclinical data shows strong efficacy and a favorable safety profile. These results are described as 'positive' and 'better than expected' by experts, indicating strong progress and future potential, despite inherent biotech risks.

Positives

• Revita demonstrated strong early signals for durable weight maintenance, with 12 of 13 participants maintaining or losing weight after GLP-1 discontinuation, contrasting sharply with typical weight regain.
• The median weight change for Revita-treated participants was stable at 0.46% (~1 pound) at 3 months, significantly better than the expected 5-6% (10-15 pounds) rebound seen with GLP-1 withdrawal.
• Revita procedure was well-tolerated with no unanticipated or serious adverse effects, indicating a favorable safety profile.
• New preclinical data for the Rejuva Smart GLP-1 gene therapy platform showed a single dose prevented obesity and hyperglycemia in high-fat diet animal models, demonstrating strong efficacy.
• Rejuva's mechanism of action is nutrient-responsive and self-limiting, activating only under metabolic stress, which suggests a potentially superior potency and tolerability profile compared to chronic systemic GLP-1 receptor agonists.
• The advancement of RJVA-001, Rejuva's first clinical candidate, towards first-in-human studies in 2026, indicates progress in a novel gene therapy approach for metabolic diseases.

Risks

• The company has a limited operating history.
• The company incurs and expects to continue incurring significant net losses for the foreseeable future.
• The company needs substantial additional financing to continue operations.
• There is uncertainty regarding the company's ability to continue as a going concern.
• The regulatory approval process for the company's product candidates is lengthy, unpredictable, and time-consuming.
• There is uncertainty regarding the outcomes and success of its clinical studies.
• Product candidates may cause serious adverse events, undesirable side effects, or have other properties that could lead to suspension/discontinuation of studies, delay/prevention of regulatory development/approval, or limit commercial profile.
• Additional time may be required to develop and obtain regulatory approval or certification for Rejuva gene therapy candidates.
• The company relies on third parties to conduct certain aspects of its preclinical and clinical studies.
• The company relies on third parties for the manufacture of sub-assembly components for Revita and materials for its Rejuva gene therapy platform.

Future Outlook

Fractyl Health anticipates significant clinical milestones, including REMAIN-1 Midpoint Cohort data in Q3 2025 and 6-month primary endpoint data from the REMAIN-1 Pivotal Cohort in H2 2026. The company also expects to dose the first patients with RJVA-001 and report preliminary clinical data in 2026, aiming to advance its gene therapy platform toward first-in-human studies and potentially redefine metabolic disease treatment with durable, disease-modifying therapies.

Management Comments

• Shelby Sullivan, M.D., Professor of Medicine at the Geisel School of Medicine at Dartmouth University, stated: "These early Revita data are better than I expected and suggest the potential to prevent the weight regain we see in practice. If these findings are sustained beyond 3 months and validated in the randomized cohort, this could become a viable solution for the many patients who would like to stop GLP-1 medications but currently can't."
• Harith Rajagopalan, M.D., Ph.D., Co-Founder and CEO of Fractyl Health, commented: "These REVEAL-1 Cohort data represent a powerful early signal of Revita's ability to sustain weight loss after GLP-1 therapy ends, which is a significant challenge in the obesity treatment landscape. With over 90 percent of patients maintaining or continuing to lose weight after a single Revita procedure, we believe Revita may be uniquely positioned to define a new therapeutic area in metabolic care: post-GLP-1 weight maintenance."
• Dr. Rajagopalan also stated regarding Rejuva: "These results underscore the transformative potential of Rejuva to offer protection from obesity and diabetes in the setting of modern environmental exposure to unhealthy diets. Unlike chronic systemic GLP-1 therapy, our approach localizes treatment to the pancreas and enables nutrient-stimulated GLP-1 secretion from beta cells, mimicking natural hormone regulation."
• Dr. Timothy Kieffer, Scientific Advisor to Fractyl Health, noted: "Systemic GLP-1 drugs have set a high bar, but their limitations are becoming increasingly evident. There is a need to deliver the therapeutic benefit of GLP-1 in a more physiologic, durable manner. Rejuva has the potential to meet this need by enabling sustained metabolic benefit from a single treatment."

Industry Context

The announcement addresses critical unmet needs in the metabolic disease landscape, particularly the challenge of weight maintenance after discontinuing GLP-1 drugs, which typically leads to significant weight regain. Fractyl Health's Revita aims to provide a durable, drug-free solution for this, potentially creating a new therapeutic area. Concurrently, its Rejuva gene therapy platform offers a novel approach to obesity and type 2 diabetes by targeting the pancreas for nutrient-responsive GLP-1 secretion, differentiating itself from chronic systemic GLP-1 receptor agonists by mimicking natural hormone regulation and potentially offering superior potency and tolerability.

Comparison to Industry Standards

• Revita's 3-month data showed median weight stability (0.46% / ~1 pound weight change) after GLP-1 discontinuation, which is significantly better than the typical 5-6% (10-15 pounds) weight rebound observed in clinical studies such as SURMOUNT-4 (tirzepatide withdrawal) and Wilding et al. (2022) after stopping GLP-1 therapy.
• Rejuva's preclinical data demonstrating prevention of obesity and hyperglycemia in high-fat diet models, with a single dose, positions it as a potentially differentiated and more durable alternative to existing chronic systemic GLP-1 therapies, which require continuous administration.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong clinical and preclinical data, which could enhance company valuation and future prospects for novel therapies in large markets (obesity, T2D).
• **Patients:** Potential for new, durable, and potentially drug-free treatment options for obesity and type 2 diabetes, addressing significant unmet needs like weight maintenance after GLP-1 discontinuation.
• **Employees:** Positive impact from company progress, successful clinical development, and potential for future commercialization, contributing to job security and growth opportunities.
• **Healthcare Providers:** New therapeutic tools could become available to address challenging metabolic conditions, offering alternatives or complements to existing treatments.

Next Steps

• Release of REMAIN-1 Midpoint Cohort data expected in Q3 2025.
• Release of 6-month primary endpoint data from the REMAIN-1 Pivotal Cohort expected in H2 2026.
• Advancement of RJVA-001 (Rejuva's first clinical candidate) toward first-in-human studies.
• Anticipated preliminary clinical data from RJVA-001 in 2026.

Key Dates

Recommendation

Keywords

Obesity, Type 2 Diabetes, GLP-1, Weight Maintenance, Gene Therapy, Clinical Trials, Metabolic Disease, Revita, Rejuva, Biotechnology, Pharmaceuticals, Medical Devices